Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

M. Marty, Francisco; Ljungman, Per; F. Chemaly, Roy; Maertens, Johan; Dadwal, Sanjeet; F. Duarte, Rafael; Haider, Shariq; J. Ullmann, Andrew; Katayama, Yuta; Brown, Janice; M. Mullane, Kathleen; Boeckh, Michael; A. Blumberg, Emily; Einsele, Hermann; R. Snydman, David; Kanda, Yoshinobu; J. DiNubile, Mark; Teal, Valerie; Wan, Hong; Murata, Yoshihiko; A. Kartsonis, Nicholas; Y. Leavitt, Randi; Badshah, Cyrus

doi:10.1056/nejmoa1706640

Public

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Published in New England Journal of Medicine • Dec 6, 2017

Authors:

Francisco M. Marty

Per Ljungman

Roy F. Chemaly

Abstract

BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we randomly assigned CMV-seropositive transplant recip...

Subject

Medicine

Hematopoietic cell

Hematopoietic stem cell transplantation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!